Drugs / PRTH-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05753722 | Mar 2023 → Sep 2027 expected | non-small cell lung carcinoma | Incendia Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-02 | Incendia Therapeutics | Results Incendia Therapeutics Presents Two Posters on its Lead Asset PRTH-101 in Thymic Cancers at the 15th International Thymic Malignancy Interest Group (ITMIG) Annual Meeting incendiatx.com ↗
Initial Phase 1 data suggest PRTH-101 contributes to disease control in recurrent/metastatic thymic epithelial carcinoma (TEC) with median progression-free survival (mPFS) of 7.9 months and 1 partial response (PR) observed |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRTH-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05753722 ↗ |
| Modality | Monoclonal antibody | “PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody” NCT05753722 ↗ |